MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Heron Therapeutics Inc

Suletud

SektorTervishoid

1.29 -0.77

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.29

Põhinäitajad

By Trading Economics

Sissetulek

-5M

-2.4M

Müük

-1.7M

37M

Kasumimarginaal

-6.401

Töötajad

122

EBITDA

-5.3M

-1.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+248.84% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-29M

238M

Eelmine avamishind

2.06

Eelmine sulgemishind

1.29

Uudiste sentiment

By Acuity

13%

87%

10 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. okt 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19. okt 2025, 23:44 UTC

Market Talk

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19. okt 2025, 23:37 UTC

Market Talk

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19. okt 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19. okt 2025, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. okt 2025, 23:09 UTC

Market Talk

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19. okt 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19. okt 2025, 22:30 UTC

Tulu

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19. okt 2025, 22:18 UTC

Market Talk

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19. okt 2025, 21:50 UTC

Market Talk

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19. okt 2025, 21:15 UTC

Market Talk

Investors Need to Change Narrative Toward Scales -- Market Talk

19. okt 2025, 19:34 UTC

Omandamised, ülevõtmised, äriostud

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19. okt 2025, 19:34 UTC

Omandamised, ülevõtmised, äriostud

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19. okt 2025, 19:33 UTC

Omandamised, ülevõtmised, äriostud

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19. okt 2025, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19. okt 2025, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19. okt 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19. okt 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19. okt 2025, 16:29 UTC

Tulu

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19. okt 2025, 11:14 UTC

Tulu

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19. okt 2025, 11:14 UTC

Tulu

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19. okt 2025, 11:14 UTC

Tulu

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18. okt 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17. okt 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. okt 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. okt 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

248.84% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  248.84%

Kõrge 6 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

10 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat